Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) Invested Capital (2016 - 2025)

RedHill Biopharma has reported Invested Capital over the past 14 years, most recently at $19.0 million for Q4 2025.

  • Quarterly Invested Capital rose 159.59% to $19.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.0 million through Dec 2025, up 159.59% year-over-year, with the annual reading at $19.0 million for FY2025, 159.59% up from the prior year.
  • Invested Capital was $19.0 million for Q4 2025 at RedHill Biopharma, up from -$4.4 million in the prior quarter.
  • Over five years, Invested Capital peaked at $113.9 million in Q3 2022 and troughed at -$37.2 million in Q4 2022.
  • The 5-year median for Invested Capital is $55.9 million (2021), against an average of $46.0 million.
  • Year-over-year, Invested Capital tumbled 226.87% in 2022 and then skyrocketed 159.59% in 2025.
  • A 5-year view of Invested Capital shows it stood at $29.4 million in 2021, then tumbled by 226.87% to -$37.2 million in 2022, then surged by 108.7% to $3.2 million in 2023, then soared by 126.25% to $7.3 million in 2024, then skyrocketed by 159.59% to $19.0 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Invested Capital are $19.0 million (Q4 2025), -$4.4 million (Q2 2025), and $7.3 million (Q4 2024).